Sugi Predict

Sugi Predict / Targets / TMPRSS11D

TMPRSS11D

Transmembrane protease serine 11D · O60235 · TMPRSS11D on Sugi Atlas →

5,356 patent compounds predicted against TMPRSS11D, 4,006 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7315371 SCHEMBL7315371 0.51 15/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7944779) 0.50 15/20
SCHEMBL1416490 SCHEMBL1416490 0.61 14/20
SCHEMBL49084 SCHEMBL49084 0.73 12/20
SCHEMBL7106028 SCHEMBL7106028 0.68 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7140902) 0.67 12/20
SCHEMBL7353953 SCHEMBL7353953 0.65 12/20
SCHEMBL7365085 SCHEMBL7365085 0.64 12/20
SCHEMBL7360255 SCHEMBL7360255 0.62 12/20
SCHEMBL7102494 SCHEMBL7102494 0.58 12/20
SCHEMBL7105052 SCHEMBL7105052 0.58 12/20
SCHEMBL7341151 SCHEMBL7341151 0.57 12/20
SCHEMBL7102489 SCHEMBL7102489 0.56 12/20
SCHEMBL7102493 SCHEMBL7102493 0.56 12/20
SCHEMBL7463636 SCHEMBL7463636 0.55 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7156972) 0.55 12/20
SCHEMBL6680363 SCHEMBL6680363 0.54 12/20
SCHEMBL7305864 SCHEMBL7305864 0.54 12/20
SCHEMBL7306031 SCHEMBL7306031 0.54 12/20
SCHEMBL2167674 SCHEMBL2167674 0.53 12/20

Clinical trials — most relevant to TMPRSS11D by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease PHASE4COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 PHASE2/PHASE3UNKNOWN
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit PHASE3WITHDRAWN
Proxalutamide Treatment for COVID-19 Female Outpatients PHASE3WITHDRAWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus PHASE2UNKNOWN
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer PHASE2COMPLETED
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia PHASE2COMPLETED
Investigation the Effect of Montelukast in COVID-19 PHASE2UNKNOWN
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer PHASE2COMPLETED
Nebulised BromAc in Healthy Volunteers PHASE1COMPLETED
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) EARLY_PHASE1UNKNOWN
Hesperidin and Diosmin for Treatment of COVID-19 EARLY_PHASE1UNKNOWN
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 EARLY_PHASE1UNKNOWN
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features nanUNKNOWN
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID nanRECRUITING
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study nanWITHDRAWN
Impact of the Genetic Polymorphism on COVID-19 in Egypt nanUNKNOWN
ACE2 Gender Differences in Stroke With COVID-19 nanCOMPLETED
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity nanWITHDRAWN
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort nanUNKNOWN
Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load. nanCOMPLETED
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids nanWITHDRAWN
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients nanCOMPLETED
Association Between Periodontitis and Coronavirus Disease (COVID-19) nanCOMPLETED
Cardiac Injury in COVID-19: a Pathology Study nanUNKNOWN
Anti-Androgen Treatment for COVID-19 nanCOMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation nanCOMPLETED
Semen Analysis Changes in Covid-19 Positivepatients nanCOMPLETED
COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TMPRSS11D binder may also engage these)

ProteinNameSimilarity
Q8VHJ4 — 1.000 Q8VHJ4 →
Q6ZMR5 — 0.998 Q6ZMR5 →
Q8VHK8 — 0.995 Q8VHK8 →
Q14C59 — 0.993 Q14C59 →
Q8BZ10 — 0.992 Q8BZ10 →
A0A182C2Z2 — 0.991 A0A182C2Z2 →
P49150 — 0.989 P49150 →
Q8BHM9 — 0.987 Q8BHM9 →
Q6ZWK6 — 0.987 Q6ZWK6 →
Q86T26 — 0.987 Q86T26 →
Q9VWU1 — 0.986 Q9VWU1 →
P29598 — 0.986 P29598 →
Q1JRP2 — 0.985 Q1JRP2 →
Q7RTY8 — 0.985 Q7RTY8 →
Q9UL52 — 0.984 Q9UL52 →
Q5S248 — 0.984 Q5S248 →
Q6IE14 — 0.984 Q6IE14 →
Q58L94 — 0.984 Q58L94 →
Q5QSK2 — 0.983 Q5QSK2 →
Q3UQ41 — 0.983 Q3UQ41 →
Q9PTU8 — 0.983 Q9PTU8 →
Q5W958 — 0.982 Q5W958 →
P86091 — 0.982 P86091 →
P15638 — 0.982 P15638 →
E5L0E5 — 0.982 E5L0E5 →
P0DJF6 — 0.982 P0DJF6 →
O97398 — 0.982 O97398 →
Q9PTL3 — 0.982 Q9PTL3 →
Q9I8X1 — 0.982 Q9I8X1 →
P14272 — 0.981 P14272 →